HONG KONG – Just one month after its $764 million initial public offering (IPO) in Hong Kong, leading Chinese pharmaceutical company Luye Pharma took a significant expansionary step with the acquisition of Beijing Jialin Pharmaceutical. Read More
TOKYO – One more Japanese company has taken a step closer to the biosimilars market through a strategic drug development alliance with a U.S. company and a drug for rheumatoid arthritis. Read More
SHANGHAI – Zai Lab Inc., of Shanghai, has received $30 million in financing from a group of international venture capital investors, led by the well-respected Qiming Venture Partners LLC, headquartered in Hong Kong. The series A funding will support Zai's pursuit of its "virtual" business model, and the in-licensing and developing of innovative drugs for global markets as well as China. Read More
Legochem Biosciences Inc. (LCB) boasts an intuitive name, hearkening to the use of Lego-like scaffolds to enable the discovery of drug candidates. But the platform is more than a toy for scientists. Read More
Beigene Co. Ltd., of Beijing, dosed the first patient in a phase I study of BGB-3111 for the treatment of cancer. BGB-3111 is an investigational oral highly selective and potent inhibitor of Bruton's tyrosine kinase, the company said. Read More
